IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040

Diabetes Research and Clinical Practice

Volumn 128, Issue , 2017, Pages 40-50

  Ogurtsova, K ^a   da Rocha Fernandes, J D ^a   Huang, Y ^a   Linnenkamp, U ^a   Guariguata, L ^a   Cho, N H ^a,b   Cavan, D ^a   Shaw, J E ^c   Makaroff, L E ^a,d  

^a International Diabetes Federation   (Belgium)

^b Ajou University School of Medicine   (South Korea)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Diabetes mellitus; Epidemiology; Gestational diabetes; Health economics; Impaired glucose tolerance; Mortality

Indexed keywords

ARTICLE; ATTRIBUTABLE RISK; DIABETES MELLITUS; HEALTH CARE COST; HUMAN; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; PREVALENCE; SYSTEMATIC REVIEW; ADULT; AGED; FEMALE; GLOBAL HEALTH; HISTORY; MALE; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; DIABETES MELLITUS; FEMALE; GLOBAL HEALTH; HISTORY, 21ST CENTURY; HUMANS; MALE; MIDDLE AGED; PREVALENCE; YOUNG ADULT;

EID: 85018528823     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2017.03.024     Document Type: Article

References (56)

1. [1] Afkarian, M., Sachs, M.C., Kestenbaum, B., Hirsch, I.B., Tuttle, K.R., Himmelfarb, J., et al. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol JASN 24 (2013), 302–308, 10.1681/ASN.2012070718.
2. [2] Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M. Age standardization of rates: a new WHO standard (GPE Discussion Paper Series: No.31). Geneva, Switzerland: World Health Organization; 2001.
3. [3] American Diabetes Association, Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36 (2013), 1033–1046, 10.2337/dc12-2625.
4. [4] Basu, S., Yoffe, P., Hills, N., Lustig, R.H., The relationship of sugar to population-level diabetes prevalence: an econometric analysis of repeated cross-sectional data. PLoS ONE, 8, 2013, e57873, 10.1371/journal.pone.0057873.
5. [5] Baxter, M., Hudson, R., Mahon, J., Bartlett, C., Samyshkin, Y., Alexiou, D., et al. Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit. Diabet Med 33 (2016), 1575–1581, 10.1111/dme.13062.
6. [6] Ben-Haroush, A., Yogev, Y., Hod, M., Epidemiology of gestational diabetes mellitus and its association with Type 2 diabetes. Diabet Med 21 (2004), 103–113, 10.1046/j.1464-5491.2003.00985.x.
7. [7] Boyle, J.P., Engelgau, M.M., Thompson, T.J., Goldschmid, M.G., Beckles, G.L., Timberlake, D.S., et al. Estimating prevalence of type 1 and type 2 diabetes in a population of African Americans with diabetes mellitus. Am J Epidemiol 149 (1999), 55–63.
8. [8] Bruno, G., Runzo, C., Cavallo-Perin, P., Merletti, F., Rivetti, M., Pinach, S., et al. Incidence of type 1 and type 2 diabetes in adults aged 30–49 years: the population-based registry in the province of Turin, Italy. Diabetes Care 28 (2005), 2613–2619.
9. [9] Buijsse, B., Simmons, R.K., Griffin, S.J., Schulze, M.B., Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol Rev 33 (2011), 46–62, 10.1093/epirev/mxq019.
10. [10] Central Intelligence Agency, Country profiles, World factbook. 2015, Central Intelligence Agency, Fairfax, USA.
11. [11] Dabelea, D., Hanson, R.L., Lindsay, R.S., Pettitt, D.J., Imperatore, G., Gabir, M.M., et al. Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships. Diabetes 49 (2000), 2208–2211, 10.2337/diabetes.49.12.2208.
12. [12] da Rocha Fernandes, J., Ogurtsova, K., Linnenkamp, U., Guariguata, L., Seuring, T., Zhang, P., et al. IDF diabetes atlas estimates of 2014 global health expenditures on diabetes. Diabetes Res Clin Pract 117 (2016), 48–54, 10.1016/j.diabres.2016.04.016.
13. [13] Degli Esposti, L., Saragoni, S., Buda, S., Sturani, A., Degli Esposti, E., Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases. Clin Outcomes Res CEOR 5 (2013), 193–201, 10.2147/CEOR.S41846.
14. [14] Diabetes UK. The cost of diabetes. Diabetes UK, London, United Kingdom; 2014.
15. [15] Entmacher, P.S., Marks, H.H., Diabetes in 1964; a world survey. Diabetes 14 (1965), 212–223.
16. [16] Evans, J.M., Newton, R.W., Ruta, D.A., MacDonald, T.M., Morris, A.D., Socio-economic status, obesity and prevalence of Type 1 and Type 2 diabetes mellitus. Diabet Med J Br Diabet Assoc 17 (2000), 478–480.
17. [17] Farran, B., Channanath, A.M., Behbehani, K., Thanaraj, T.A., Predictive models to assess risk of type 2 diabetes, hypertension and comorbidity: machine-learning algorithms and validation using national health data from Kuwait–a cohort study. BMJ Open, 3, 2013, 10.1136/bmjopen-2012-002457.
18. [18] Gray, B.J., Bracken, R.M., Turner, D., Morgan, K., Thomas, M., Williams, S.P., et al. Different type 2 diabetes risk assessments predict dissimilar numbers at “high risk”: a retrospective analysis of diabetes risk-assessment tools. Br J Gen Pract J R Coll Gen Pract 65 (2015), e852–860, 10.3399/bjgp15X687661.
19. [19] Guariguata, L., Whiting, D., Weil, C., Unwin, N., The International Diabetes Federation diabetes atlas methodology for estimating global and national prevalence of diabetes in adults. Diabetes Res Clin Pract 94 (2011), 322–332, 10.1016/j.diabres.2011.10.040.
20. [20] Herman, W.H., Edelstein, S.L., Ratner, R.E., Montez, M.G., Ackermann, R.T., Orchard, T.J., et al. Effectiveness and cost-effectiveness of diabetes prevention among adherent participants. Am J Manage Care 19 (2013), 194–202.
21. [21] Holman, N., Young, B., Gadsby, R., Current prevalence of Type 1 and Type 2 diabetes in adults and children in the UK. Diabet Med J Br Diabet Assoc 32 (2015), 1119–1120, 10.1111/dme.12791.
22. [22] IDF Diabetes Atlas Group, Update of mortality attributable to diabetes for the IDF Diabetes Atlas: estimates for the year 2011. Diabetes Res Clin Pract 100 (2013), 277–279, 10.1016/j.diabres.2013.02.005.
23. [23] International Diabetes Federation, IDF Diabetes atlas. 6th ed., 2013, International Diabetes Federation, Brussels, Belgium.
24. [24] International Diabetes Federation, IDF Diabetes Atlas. 5th ed., 2011, International Diabetes Federation, Brussels, Belgium.
25. [25] International Diabetes Federation, IDF Diabetes Atlas. 4th ed., 2009, International Diabetes Federation, Brussels, Belgium.
26. [26] International Diabetes Federation, IDF Diabetes Atlas. 3rd ed., 2006, International Diabetes Federation, Brussels, Belgium.
27. [27] International Diabetes Federation, IDF Diabetes Atlas. 2nd ed., 2003, International Diabetes Federation, Brussels, Belgium.
28. [28] International Diabetes Federation, IDF Diabetes Atlas. 1st ed., 2000, International Diabetes Federation, Brussels, Belgium.
29. [29] Kaul, P., Savu, A., Nerenberg, K.A., Donovan, L.E., Chik, C.L., Ryan, E.A., et al. Impact of gestational diabetes mellitus and high maternal weight on the development of diabetes, hypertension and cardiovascular disease: a population-level analysis. Diabet Med J Br Diabet Assoc 32 (2015), 164–173, 10.1111/dme.12635.
30. [30] Linnenkamp, U., Guariguata, L., Beagley, J., Whiting, D.R., Cho, N.H., The IDF Diabetes Atlas methodology for estimating global prevalence of hyperglycaemia in pregnancy. Diabetes Res Clin Pract 103 (2014), 186–196, 10.1016/j.diabres.2013.11.004.
31. [31] Li, W., Katzmarzyk, P.T., Horswell, R., Wang, Y., Johnson, J., Hu, G., HbA1c and all-cause mortality risk among patients with type 2 diabetes. Int J Cardiol 202 (2016), 490–496, 10.1016/j.ijcard.2015.09.070.
32. [32] Makaroff, L.E., Cavan, D., Which biochemical assay is best for measuring diabetes prevalence?. Lancet Diabetes Endocrinol 3 (2015), 582–583, 10.1016/S2213-8587(15)00203-X.
33. [33] NCD Risk Factor Collaboration (NCD-RisC), Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet Lond Engl 387 (2016), 1513–1530, 10.1016/S0140-6736(16)00618-8.
34. [34] Ogurtsova, K., da Rocha Fernandes, J., Cavan, D., Makaroff, L.E., IDF Atlas Group. Global estimates for undiagnosed diabetes for the 2015 IDF diabetes Atlas: a revision of the methodology. 2016, American Diabetes Association Scientific Sessions (Poster), New Orleans, USA.
35. [35] Ogurtsova, K., Guariguata, L., Linnenkamp, U., Fernandes, J.D.R., Cho, N.H., Makaroff, L.E., Regional differences in diabetes prevalence by age and urban/rural setting (poster). Diabetes 64 (2015), A382–A466, 10.2337/db15-1472-1800.
36. [36] Ogurtsova K, Guariguata L, Whiting D, Unwin N, Weil C, da Rocha Fernandes J. et al. 2015. Sensitivity analysis of the global diabetes prevalence estimate in the IDF Diabetes Atlas (Poster). In: International diabetes epidemiology group. Vancouver.
37. [37] Ogurtsova, K., Guariguata, L., Whiting, D., Unwin, N., Weil, C., Fernandes, J.D.R., et al. Incorporating uncertainty measurement in the International Diabetes Federation Diabetes Atlas methodology for estimating global and national prevalence of diabetes in adults (Poster). Arch Public Health, 73, 2015, 10.1186/2049-3258-73-S1-P31.
38. [38] Razavian, N., Blecker, S., Schmidt, A.M., Smith-McLallen, A., Nigam, S., Sontag, D., Population-level prediction of type 2 diabetes from claims data and analysis of risk factors. Big Data 3 (2015), 277–287, 10.1089/big.2015.0020.
39. [39] R Core Team, R: A language and environment for statistical computing. 2012, R Foundation for Statistical Computing, Vienna, Austria.
40. [40] Rivera, L.A., Lebenbaum, M., Rosella, L.C., The influence of socioeconomic status on future risk for developing Type 2 diabetes in the Canadian population between 2011 and 2022: differential associations by sex. Int J Equity Health, 14, 2015, 101, 10.1186/s12939-015-0245-0.
41. [41] Roglic, G., Unwin, N., Mortality attributable to diabetes: estimates for the year 2010. Diabetes Res Clin Pract 87 (2010), 15–19, 10.1016/j.diabres.2009.10.006.
42. [42] Rosella, L.C., Mustard, C.A., Stukel, T.A., Corey, P., Hux, J., Roos, L., et al. The role of ethnicity in predicting diabetes risk at the population level. Ethn Health 17 (2012), 419–437, 10.1080/13557858.2012.654765.
43. [43] Saaty, T.L., Decision making with the analytic hierarchy process. Int J Serv Sci 1 (2008), 83–97.
44. [44] Siegel, K.R., Echouffo-Tcheugui, J.B., Ali, M.K., Mehta, N.K., Narayan, K.M., Chetty, V., Societal correlates of diabetes prevalence: an analysis across 94 countries. Diabetes Res Clin Pract 96 (2012), 76–83, 10.1016/j.diabres.2011.11.014.
45. [45] Thoopputra, T., Pongmesa, T., Newby, D.A., Schneider, J., Li, S.C., Opportunistic risk screening for type 2 diabetes: exploring of application of diabetes risk assessment tool in community pharmacy in Australia and Thailand. Value Health Reg Issues 9 (2016), 1–7, 10.1016/j.vhri.2015.03.022.
46. [46] United Nations, Department of Economic and Social Affairs, Population Division, World population prospects: the 2015 revision. 2015, World Population Prospects, New York, USA.
47. [47] United Nations, Department of Economic and Social Affairs, Population Division, World urbanization prospects: The 2014 revision. 2014, United Nations Population Division, New York, USA.
48. [48] Vamos, E.P., Harris, M., Millett, C., Pape, U.J., Khunti, K., Curcin, V., et al. Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study. BMJ, 345, 2012, e5567.
49. [49] van Dooren, F.E.P., Nefs, G., Schram, M.T., Verhey, F.R.J., Denollet, J., Pouwer, F., Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PLoS ONE, 8, 2013, e57058, 10.1371/journal.pone.0057058.
50. [50] Warren, B., Pankow, J.S., Matsushita, K., Punjabi, N.M., Daya, N.R., Grams, M., et al. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol, 2016, 10.1016/S2213-8587(16)30321-7.
51. [51] Wild, S., Roglic, G., Green, A., Sicree, R., King, H., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004), 1047–1053.
52. [52] World Bank Group. World bank country and lending groups. Data Help Desk; 2015.
53. [53] World Health Organization. Global report on diabetes. Geneva, Switzerland; 2016.
54. [54] World Health Organization, World Health Statistics 2016: monitoring health for the sustainable development goals. 2016, World Health Organization, Geneva, Switzerland.
55. [55] World Health Organization. Health in 2015, from MDGs, millennium development goals to SDGs, sustainable development goals; 2015.
56. [56] World Health Organization, Global status report on noncommunicable diseases 2014: attaining the nine global noncommunicable diseases targets; a shared responsibility. 2014, World Health Organization, Geneva.